One To Watch

Acadia Pharmaceuticals

Company Overview

A San Diego-based CNS-focused biopharmaceutical company commercializing Nuplazid (pimavanserin) for Parkinson's disease psychosis while advancing a pipeline targeting neuropsychiatric conditions with significant unmet need. Acadia's commercial foundation rests on pimavanserin, the first and only FDA-approved therapy for hallucinations and delusions in Parkinson's disease psychosis. The company applies its serotonin receptor expertise across dementia-related psychosis, Rett syndrome, and major depressive disorder, building a franchise anchored in diseases with limited treatment options.

Headquarters and Global Presence

Acadia is headquartered in San Diego, California, with operations primarily concentrated in the United States. The company maintains a commercial infrastructure focused on neurology and psychiatry prescribers across the US market.

Founding and History

Acadia was founded in 1993 and spent its early years developing small-molecule compounds targeting CNS receptors. The company's trajectory changed decisively with the clinical development of pimavanserin, culminating in FDA approval of Nuplazid in April 2016 — the first drug approved specifically for Parkinson's disease psychosis. A second FDA approval followed in June 2024, expanding Nuplazid's label to cover hallucinations and delusions associated with Parkinson's disease psychosis under an updated regulatory action. Acadia also gained FDA approval for trofinetide (Daybue) in March 2023 for Rett syndrome through its acquisition of Neuren Pharmaceuticals' US rights.

Therapy Areas and Focus

Acadia is focused primarily on neuropsychiatric and neurodevelopmental disorders, with commercial products spanning Parkinson's disease psychosis and Rett syndrome. The company's pipeline extends into dementia-related psychosis, where hallucinations and delusions affect a substantial proportion of Alzheimer's patients and represent a major unmet clinical need. Major depressive disorder constitutes an additional pipeline target, addressed through pimavanserin's adjunctive potential. These areas share a common thread: serotonergic and glutamatergic dysregulation driving behavioral and cognitive symptoms inadequately addressed by existing therapies.

Technology Platforms and Modalities

Acadia's core platform centers on selective serotonin inverse agonist and antagonist (SSIA) pharmacology, most fully realized in pimavanserin's targeting of 5-HT2A receptors. Unlike dopamine-blocking antipsychotics, pimavanserin achieves antipsychotic effect without D2 receptor antagonism, avoiding the motor side effects that make conventional antipsychotics problematic in Parkinson's patients. This mechanistic differentiation underpins both the commercial franchise and the company's next-generation compound, ACP-204, an optimized 5-HT2A inverse agonist designed for improved tolerability and exposure. Trofinetide operates through a distinct mechanism, acting as a synthetic analog of the amino-terminal tripeptide of IGF-1 to address synaptic dysfunction in Rett syndrome.

Key Pipeline and Programs

Pimavanserin (Nuplazid) is an oral 5-HT2A inverse agonist approved for Parkinson's disease psychosis and under investigation as adjunctive therapy for major depressive disorder (Phase III, CLARITY study). The dementia-related psychosis (DRP) program, targeting hallucinations and delusions across Alzheimer's, Lewy body, and vascular dementia subtypes, was subject to an FDA Complete Response Letter in 2021; Acadia has continued to work toward a regulatory path for this indication.

ACP-204 is Acadia's next-generation 5-HT2A inverse agonist, engineered for a differentiated pharmacokinetic and safety profile compared to pimavanserin. It is in Phase II/III development for Alzheimer's disease psychosis, positioning it as a potential successor asset in the DRP space where pimavanserin faced regulatory headwinds.

Trofinetide (Daybue) is an approved oral IGF-1 tripeptide analog for Rett syndrome in adults and pediatric patients aged two years and older, commercialized following Acadia's licensing of US rights from Neuren Pharmaceuticals. Post-approval commercial uptake and managed care access have been key execution priorities for this asset.

Recent Developments

The FDA approved Nuplazid for hallucinations and delusions associated with Parkinson's disease psychosis in June 2024, reinforcing the product's regulatory standing and commercial positioning. Roger Mills was appointed Executive Vice President in June 2024, signaling continued investment in senior leadership to support pipeline and commercial execution. ACP-204's Phase II/III program in Alzheimer's disease psychosis represents the company's most closely watched near-term catalyst, with data readouts anticipated to clarify the asset's regulatory and commercial prospects.

Key Personnel

Steven Davis serves as President and Chief Executive Officer, having led the company through the commercialization of both Nuplazid and Daybue. Roger Mills joined as Executive Vice President in June 2024, bringing additional leadership capacity to the company's operational and pipeline functions. Mark Schneyer has served as Executive Vice President and Chief Legal Officer, supporting the company's regulatory strategy and governance.

Strategic Partnerships

Acadia secured US commercialization rights to trofinetide from Australia-based Neuren Pharmaceuticals, a deal that delivered Acadia its second commercial product in Daybue following the 2023 FDA approval. The company has not disclosed major co-development partnerships for its pimavanserin or ACP-204 programs, pursuing those assets independently. Commercial contracting and managed care access agreements with pharmacy benefit managers represent ongoing strategic priorities given Daybue's specialty pricing profile.

FAQ Section

Acadia operates two distinct commercial franchises: Nuplazid targeting neurologists and psychiatrists treating Parkinson's disease psychosis, and Daybue addressing a rare pediatric neurodevelopmental condition through specialist centers. The Daybue launch introduced managed care access challenges given its high annual cost, requiring dedicated reimbursement infrastructure. Nuplazid remains the larger revenue contributor, while Daybue's growth trajectory depends on payer coverage expansion and patient identification.

Parkinson's disease psychosis arises partly from serotonergic dysregulation, and dopamine-blocking antipsychotics — the standard approach to psychosis elsewhere — exacerbate motor symptoms in Parkinson's patients by blocking D2 receptors already depleted by the disease. Pimavanserin's selectivity for 5-HT2A receptors allows antipsychotic benefit without dopaminergic interference, making it mechanistically suited to this population. This selectivity was the scientific rationale underpinning the original FDA approval and continues to define Acadia's competitive positioning.

ACP-204 is engineered with an optimized pharmacokinetic profile and improved tolerability characteristics compared to pimavanserin, addressing some of the safety signals that contributed to the Complete Response Letter Acadia received for pimavanserin in dementia-related psychosis in 2021. The compound retains the 5-HT2A inverse agonist mechanism but is designed to deliver a cleaner exposure profile in an elderly, multi-morbid patient population. Success in Phase II/III would position ACP-204 as a potential first approved therapy for Alzheimer's disease psychosis.

Pimavanserin has been investigated as an adjunctive treatment for major depressive disorder in patients with inadequate response to standard antidepressants, pursued through the Phase III CLARITY program. The rationale is that 5-HT2A modulation can augment antidepressant response, a mechanism consistent with prior evidence from other serotonergic adjunctive agents. This program, if successful, would substantially expand the addressable market for pimavanserin well beyond the Parkinson's disease psychosis indication.

Acadia's pipeline is concentrated in three neuropsychiatric and neurodevelopmental areas: Parkinson's disease psychosis and dementia-related psychosis (through pimavanserin and ACP-204), Rett syndrome (through Daybue), and treatment-resistant depression (through adjunctive pimavanserin). All three reflect the company's strategy of targeting disorders with documented serotonergic or synaptic dysfunction and absent or inadequate approved therapies. The through-line is CNS diseases where mechanism-driven differentiation can support both regulatory approval and premium pricing.

Acadia is a commercial-stage company with two FDA-approved products, making pipeline progression rather than initial proof-of-concept the central developmental task. ACP-204 in Alzheimer's disease psychosis is the highest-priority pipeline milestone, with Phase II/III data anticipated to determine whether Acadia can re-enter the DRP space after the pimavanserin regulatory setback. The MDD adjunctive program for pimavanserin represents a second near-term readout with significant revenue implications if Phase III data support a label expansion.

Key watchpoints for Acadia include:

ACP-204 Phase II/III data in Alzheimer's disease psychosis, the most consequential near-term binary event for the pipeline
Pimavanserin Phase III CLARITY readout in major depressive disorder, which could reframe Nuplazid's commercial ceiling
Daybue managed care access trajectory — payer coverage expansion is the primary lever for revenue growth in Rett syndrome
Regulatory and safety scrutiny of pimavanserin, given the prior CRL history in dementia-related psychosis
Generic competition timeline for pimavanserin, which will eventually pressure the core franchise despite patent protections

Want to Update your Company's Profile?